Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

FHTX - Foghorn Therapeutics Inc. So'nggi... | Finranks

Home

/

FHTX

F

Foghorn Therapeutics Inc. (FHTX)

NGM – Real vaqt narxi. Valyuta: USD

6.64

+0.05 (0.69%)

Bozor ochiq: Aug 12, 2026, 11:30 AM EDT

6.59

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.28 per share a year ago.

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027 - Accelerating a novel oral small molecule in immunology and inflammation toward IND in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $168 million ; cash runway into the first half of 2028 WATERTOWN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the second quarter ended June 30, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027 - Accelerating a novel oral small molecule in immunology and inflammation toward IND in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $168 million ; cash runway into the first half of 2028 WATERTOWN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the second quarter ended June 30, 2026.